<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Albireo Pharma, Inc.

    verified_userVerify Profile
    Companies » Health Care » Pharmaceuticals & Biotechnology » Pharmaceuticals

    About Albireo Pharma, Inc.

    Albireo is a clinical-stage biopharmaceutical company focused on the development and potential commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. We have deep expertise in bile acid biology and a pipeline of clinical and nonclinical programs. Our parent company, Albireo Pharma, Inc., is located in Boston, Massachusetts and our key operating subsidiary, Albireo AB, is located in Gothenburg, Sweden. We were spun out from AstraZeneca in 2008. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Ron Cooper
    • FOUNDED
      2003
    • EMPLOYEES
      20
    • SECTOR
      Pharmaceuticals & Biotechnology
    • SUBSECTOR
      Pharmaceuticals

    Company Tags

    No articles found.

    Editas Medicine, Inc.

    Editas Medicine, Inc.

    As a leading genome editing company, Editas Medicine is focused on translating the...

    As a leading genome editing company, Editas Med...

    Filing Type:    PU
    Microbot Medical Inc.

    Microbot Medical Inc.

    Microbot™, which was founded in 2010 and commenced operations in 2011, became a ...

    Microbot™, which was founded in 2010 and comm...

    Filing Type:    PU
    Seattle Genetics, Inc.

    Seattle Genetics, Inc.

    Founded 20 years ago, Seattle Genetics was built on a foundation of scientific inn...

    Founded 20 years ago, Seattle Genetics was buil...

    Filing Type:    PU
    Marker Therapeutics, Inc.

    Marker Therapeutics, Inc.

    We are a clinical-stage immuno-oncology company specializing in the development an...

    We are a clinical-stage immuno-oncology company...

    Filing Type:    PU
    Satsuma Pharmaceuticals, Inc.

    Satsuma Pharmaceuticals, Inc.

    With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma...

    With operations in South San Francisco, CA and ...

    Filing Type:    PU
    Verax Research Services, Inc.

    Verax Research Services, Inc.

    Knowledge Begets Confidence. Founded by proven and trusted Pharmaceutical and Medi...

    Knowledge Begets Confidence. Founded by proven ...

    Filing Type:    RA
    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals, Inc.

    Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...

    Mirum Pharmaceuticals Inc. is a clinical-stage ...

    Filing Type:    PU
    GENFIT S.A.

    GENFIT S.A.

    GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and de...

    GENFIT is a late-stage biopharmaceutical compan...

    Filing Type:    PU
    Dicerna Pharmaceuticals, Inc.

    Dicerna Pharmaceuticals, Inc.

    Dicerna is a biopharmaceutical company focused on the discovery and development of...

    Dicerna is a biopharmaceutical company focused ...

    Filing Type:    PU
    Edesa Biotech, Inc.

    Edesa Biotech, Inc.

    Edesa Biotech Inc. is a clinical-stage biopharmaceutical company founded by expert...

    Edesa Biotech Inc. is a clinical-stage biopharm...

    Filing Type:    PU
    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics, Inc.

    Protagonist Therapeutics is a clinical stage biopharmaceutical company that utiliz...

    Protagonist Therapeutics is a clinical stage bi...

    Filing Type:    PU
    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc.

    Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing ...

    Seres Therapeutics, Inc. is a microbiome therap...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.